Advertisement
Advertisement
U.S. markets close in 5 hours 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Schmitt Industries, Inc. (SMIT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0100+0.0800 (+4.15%)
As of 09:54AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.9300
Open2.0100
Bid1.9800 x 4000
Ask2.0100 x 2200
Day's Range1.9798 - 2.0100
52 Week Range1.8300 - 6.7600
Volume2,776
Avg. Volume26,833
Market Cap7.69M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.8460
Earnings DateApr 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 23, 1994
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SMIT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Schmitt Industries, Inc.
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
Advertisement
Advertisement